Efficacy and Safety Evaluation of LY3437943 in Patients with Severe Obesity and Established Cardiovascular Disease: A Randomized, Double-Blind, Phase 3 Trial

The primary objective of this study is to evaluate the **efficacy** and **safety** of retatrutide, administered once weekly, in participants with severe **obesity** and established **cardiovascular disease** (CVD). This is clinically relevant as it aims to address the dual burden of obesity and CVD, which are significant contributors to morbidity and mortality. The study seeks to determine whether retatrutide can effectively manage these conditions, potentially improving patient outcomes and quality of life.

The clinical trial involves a total of **1411 participants** who are being evaluated for the efficacy and safety of retatrutide administered once weekly. The study population includes both **male and female** subjects, encompassing an **age range** that includes adults and older adults. Participants have been selected based on their diagnosis of **obesity** and established **cardiovascular disease**. The trial population also includes individuals with a history of unsuccessful dietary weight loss efforts. The study considers lifestyle factors such as previous weight loss attempts, which are relevant to the trial's focus on obesity. The selection process ensures a diverse representation of individuals with these medical conditions, and the trial includes a vulnerable population. The study does not specify any particular dietary or physical activity requirements beyond the inclusion criteria.

The clinical trial is designed as a **randomized, double-blind, controlled** study to evaluate the efficacy and safety of **Retatrutide** in participants with **obesity** and established **cardiovascular disease**. The trial will compare the effects of Retatrutide, administered as a **solution for injection** via **subcutaneous injection**, against a placebo. The study is set to commence recruitment on September 4, 2023, and is estimated to conclude by February 17, 2026, with a total duration of approximately 30 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on criteria such as having obesity, established heart disease, and a history of unsuccessful dietary weight loss efforts. Following successful screening, participants will be randomized to receive either Retatrutide or placebo. The primary endpoint of the study is the percent change from baseline in body weight. Throughout the trial, participants will attend regular follow-up visits to monitor their health status, adherence to the treatment regimen, and any adverse events. These visits are crucial for ensuring participant safety and collecting data on the investigational product's efficacy.

The expected length of participant involvement in the study is aligned with the trial's overall duration, subject to individual health conditions and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the long-term effects of the treatment and gather comprehensive data for analysis.

The clinical trial involves the administration of **Retatrutide**, an experimental medication developed by Eli Lilly and Company Limited. Retatrutide is formulated as a **solution for injection** and is administered via **subcutaneous injection**. The active substance in Retatrutide is LY3437943 sodium, classified as a protein of other origin. The pharmaceutical form is consistent across all doses, and the medication is not a pediatric formulation. The dosing schedule for Retatrutide is once weekly, with a maximum treatment period of one week. The trial does not specify a maximum daily or total dose amount, indicating that the dosing is likely determined by the study protocol. Compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the treatment regimen.

In addition to the experimental treatment, a **placebo injection** is used as a comparator in the study. The placebo is designed to mimic the administration of Retatrutide but does not contain any active pharmaceutical ingredients. The placebo serves as a control to evaluate the efficacy and safety of Retatrutide in participants with severe obesity and established cardiovascular disease. The placebo is administered in the same manner as Retatrutide, ensuring that the study remains double-blind and that neither the participants nor the investigators are aware of the treatment assignments. This design helps to eliminate bias and allows for a more accurate assessment of the experimental medication's effects.

The efficacy of the investigational medicinal product, **Retatrutide**, will be assessed in a randomized, double-blind, Phase 3 clinical trial. The primary endpoint for evaluating efficacy is the percent change from baseline in body weight. This parameter will be measured to determine the effectiveness of Retatrutide administered once weekly compared to a placebo in participants with severe obesity and established cardiovascular disease.

The trial will involve the administration of Retatrutide as a solution for injection via subcutaneous injection. The efficacy assessments will be conducted at specified intervals throughout the study duration, although specific timepoints are not detailed in the provided data. The collection and analysis of efficacy data will be performed using standardized methods appropriate for the clinical trial setting. The trial aims to provide robust data on the efficacy of Retatrutide in the target population, contributing to the understanding of its potential benefits in managing obesity and cardiovascular conditions.